Therapy of Type 2 Diabetes

Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity

Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860 · see citing works

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works

2018 ESC/ESH Guidelines for the management of arterial hypertension

Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286 · see citing works

The Physical Activity Guidelines for Americans

Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755 · cited 1× · see citing works

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · see citing works

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1× · see citing works

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · see citing works

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382 · see citing works

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · see citing works

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · see citing works

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · see citing works

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · see citing works

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162 · see citing works

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908 · see citing works

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577 · see citing works

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · see citing works

Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · see citing works

Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial

Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · see citing works

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial

Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829 · see citing works

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 1× · see citing works

Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report

Evert, A. B., Dennison, M., Gardner, C. D., Garvey, W. T., Lau, K. H. K., MacLeod, J., Mitri, J., Pereira, R. F., Rawlings, K., Robinson, S., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0014 · Cited by 1,496 · see citing works

Physical Activity Guidelines for Americans

Bushman, B. A. (2019) · ACSMʼs Health & Fitness Journal · doi:10.1249/fit.0000000000000472 · Cited by 1,326 · see citing works

Liraglutide and renal outcomes in type 2 diabetes

Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253 · see citing works

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084 · see citing works

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975 · see citing works

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2016) · New England Journal of Medicine · doi:10.1056/nejmc1600827 · Cited by 700 · see citing works

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

Mosenzon, O., Wiviott, S. D., Cahn, A., Rozenberg, A., Yanuv, I., Goodrich, E. L., Murphy, S. A., Heerspink, H. J. L., Zelniker, T. A., Dwyer, J. P., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30180-9 · Cited by 684 · see citing works

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638 · see citing works

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial

Rosenstock, J., Kahn, S. E., Johansen, O. E., Zinman, B., Espeland, M. A., Woerle, H. J., Pfarr, E., Keller, A., Mattheus, M., Baanstra, D., et al. (2019) · JAMA · doi:10.1001/jama.2019.13772 · Cited by 612 · see citing works

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis

Bethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599 · see citing works

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582 · see citing works

Efficacy and safety of degludec versus glargine in type 2 diabetes.

Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615692 · Cited by 574 · see citing works

Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis

Pan, A., Wang, Y., Talaei, M., Hu, F. B., & Wu, T. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00316-2 · Cited by 563 · see citing works

Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus

Kato, E. T., Silverman, M. G., Mosenzon, O., Zelniker, T. A., Cahn, A., Furtado, R. H. M., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.040130 · Cited by 557 · see citing works

Dietary and nutritional approaches for prevention and management of type 2 diabetes

Forouhi, N. G., Misra, A., Mohan, V., Taylor, R., & Yancy, W. S. (2018) · BMJ · doi:10.1136/bmj.k2234 · Cited by 493 · see citing works

Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes

Palmer, S. C., Mavridis, D., Nicolucci, A., Johnson, D. W., Tonelli, M. A., Craig, J. C., Maggo, J. K., Gray, V., Berardis, G. D., Ruospo, M., et al. (2016) · JAMA · doi:10.1001/jama.2016.9400 · Cited by 423 · see citing works

Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.

Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412 · see citing works

Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes

Zheng, S. L., Roddick, A., Agha-Jaffar, R., Shun-Shin, M. J., Francis, D. P., Oliver, N. S., & Meeran, K. M. (2018) · JAMA · doi:10.1001/jama.2018.3024 · Cited by 402 · see citing works

Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes

Griffin, S. J., Leaver, J. K., & Irving, G. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4337-9 · Cited by 398 · see citing works

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG outcome randomised, placebo-controlled trial

Cherney, D. Z. I., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., von Eynatten, M., & Wanner, C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30182-1 · Cited by 383 · see citing works

Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review

Khunti, K. K., Gomes, M. B., Pocock, S., Shestakova, M. V., Pintat, S., Fenici, P., Hammar, N., & Medina, J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13088 · Cited by 376 · see citing works

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

Gough, S. C. L., Bode, B. W., Woo, V. C., Rodbard, H. W., Linjawi, S., Poulsen, P., Damgaard, L. H., & Buse, J. B. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70174-3 · Cited by 367 · see citing works

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction

Furtado, R. H. M., Bonaca, M. P., Raz, I., Zelniker, T. A., Mosenzon, O., Cahn, A., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.039996 · Cited by 335 · see citing works

Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor

Fralick, M., Schneeweiss, S., & Patorno, E. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1701990 · Cited by 334 · see citing works

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

Vilsbøll, T., Bain, S. C., Leiter, L. A., Lingvay, I., Matthews, D., Simó, R., Helmark, I. C., Wijayasinghe, N., & Larsen, M. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13172 · Cited by 318 · see citing works

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

Sattar, N. A., McLaren, J. B., Kristensen, S. L., Preiss, D., & McMurray, J. J. V. (2016) · Diabetologia · doi:10.1007/s00125-016-3956-x · Cited by 310 · see citing works

Understanding the mechanisms of reversal of type 2 diabetes

Taylor, R., Al-Mrabeh, A., & Sattar, N. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30076-2 · Cited by 299 · see citing works

SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials

Puckrin, R., Saltiel, M., Reynier, P., Azoulay, L., Yu, O. H. Y., & Filion, K. B. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1116-0 · Cited by 284 · see citing works

Metformin in cancer

Mallik, R., & Chowdhury, T. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.023 · Cited by 266 · see citing works

Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials

Monami, M., Åhrén, B., Dicembrini, I., & Mannucci, E. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12000 · Cited by 259 · see citing works

Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): <scp>D</scp> ata from randomized controlled trials

Monami, M., Nreu, B., Scatena, A., Cresci, B., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12926 · Cited by 243 · see citing works

SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System

Fadini, G. P., Bonora, B. M., & Avogaro, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4301-8 · Cited by 242 · see citing works

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

Storgaard, H., Gluud, L. L., Bennett, C., Grøndahl, M. F. G., Christensen, M., Knop, F. K., & Vilsbøll, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166125 · Cited by 240 · see citing works

Benefits of the Mediterranean diet: Epidemiological and molecular aspects

Serra‐Majem, L., Román‐Viñas, B., Sánchez‐Villegas, A., Guasch‐Ferré, M., Corella, D., & Vecchia, C. L. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.06.001 · Cited by 240 · see citing works

Identification of barriers to insulin therapy and approaches to overcoming them

Russell‐Jones, D., Pouwer, F., & Khunti, K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13132 · Cited by 238 · see citing works

Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes

Diamant, M., Nauck, M. A., Shaginian, R. M., Malone, J. K., Cleall, S., Reaney, M. D., de Vries, D., Hoogwerf, B. J., MacConell, L., Wolffenbuttel, B. H. R., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0876 · Cited by 229 · see citing works

Mortality risk among sulfonylureas: a systematic review and network meta-analysis

Simpson, S. H., Lee, J., Choi, S., Vandermeer, B., Abdelmoneim, A. S., & Featherstone, T. R. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70213-x · Cited by 222 · see citing works

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA ^® )

Marx, N., Rosenstock, J., Kahn, S. E., Zinman, B., Kastelein, J. J., Lachin, J. M., Espeland, M. A., Bluhmki, E., Mattheus, M., Ryckaert, B., et al. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115570301 · Cited by 212 · see citing works

Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial

Billings, L. K., Doshi, A., Gouet, D., Oviedo, A., Rodbard, H. W., Tentolouris, N., Grøn, R., Halladin, N., & Jódar, E. (2018) · Diabetes Care · doi:10.2337/dc17-1114 · Cited by 196 · see citing works

Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies

Azoulay, L., & Suissa, S. (2017) · Diabetes Care · doi:10.2337/dc16-1943 · Cited by 195 · see citing works

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3a): the DERIVE Study

Fioretto, P., Del Prato, S., Buse, J. B., Goldenberg, R., Giorgino, F., Reyner, D., Langkilde, A. M., Sjöström, C. D., Sartipy, P., & On Behalf of the DERIVE Study Investigators (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13413 · Cited by 195 · see citing works

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Correia, L. C. L., Latado, A., & Porzsolt, F. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1611289 · Cited by 194 · see citing works

Resistance Exercise Intensity is Correlated with Attenuation of HbA1c and Insulin in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

Liu, Y., Ye, W., Chen, Q., Zhang, Y., Kuo, C.-H., & Korivi, M. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16010140 · Cited by 176 · see citing works

Definition, Klassifikation und Diagnostik des Diabetes mellitus

Nauck, M. A., Petermann, A., Müller‐Wieland, D., Kerner, W., Müller, U., Landgraf, R., Freckmann, G., & Heinemann, L. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-115953 · Cited by 175 · see citing works

Cardiorespiratory fitness, muscular strength and risk of type 2 diabetes: a systematic review and meta-analysis

Tarp, J., Støle, A. P., Blond, K., & Grøntved, A. (2019) · Diabetologia · doi:10.1007/s00125-019-4867-4 · Cited by 173 · see citing works

Lack of evidence for a harmful effect of sodium‐glucose co‐transporter 2 ( SGLT2 ) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta‐analysis of randomized controlled trials

Tang, H., Li, D., Zhang, J. J., Hsu, Y., Wang, T., Zhai, S., & Song, Y. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12742 · Cited by 167 · see citing works

Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function

Lazarus, B., Wu, A., Shin, J., Sang, Y., Alexander, G. C., Secora, A. M., Inker, L. A., Coresh, J., Chang, A. R., & Grams, M. E. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.0292 · Cited by 166 · see citing works

Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population‐based study of older women and men with diabetes

Lega, I. C., Bronskill, S. E., Campitelli, M. A., Guan, J., Stall, N. M., Lam, K., McCarthy, L. M., Gruneir, A., & Rochon, P. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13820 · Cited by 166 · see citing works

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial

Pratley, R. E., Eldor, R., Raji, A., Golm, G. T., Huyck, S. B., Qiu, Y., Sunga, S., Johnson, J. R., Terra, S. G., Mancuso, J. P., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13194 · Cited by 162 · see citing works

Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial

Inzucchi, S. E., Iliev, H., Pfarr, E., & Zinman, B. (2018) · Diabetes Care · doi:10.2337/dc17-1551 · Cited by 162 · see citing works

S2k-Leitlinie nicht alkoholische Fettlebererkrankungen

Roeb, E., Steffen, H., Bantel, H., Baumann, U., Canbay, A. E., Demir, M., Drebber, U., Geier, A., Hampe, J., Hellerbrand, C., et al. (2015) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0035-1553193 · Cited by 161 · see citing works

Efficacy of the Telemedical Lifestyle intervention Program TeLiPro in Advanced Stages of Type 2 Diabetes: A Randomized Controlled Trial

Kempf, K., Altpeter, B., Berger, J., Reuß, O., Fuchs, M., Schneider, M., Gärtner, B., Niedermeier, K., & Martin, S. (2017) · Diabetes Care · doi:10.2337/dc17-0303 · Cited by 160 · see citing works

Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis

Usman, M. S., Siddiqi, T. J., Memon, M. M., Khan, M. S., Rawasia, W. F., Talha Ayub, M., Sreenivasan, J., & Golzar, Y. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318755531 · Cited by 160 · see citing works

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Leiter, L. A., Bain, S. C., Hramiak, I., Jódar, E., Madsbad, S., Gondolf, T., Hansen, T., Holst, I., & Lingvay, I. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0871-8 · Cited by 159 · see citing works

Physical Exercise as Therapy for Type 2 Diabetes Mellitus: From Mechanism to Orientation

Yang, D., Yang, Y., Li, Y., & Han, R. (2019) · Annals of Nutrition and Metabolism · doi:10.1159/000500110 · Cited by 157 · see citing works

ESC/EAS Guidelines for the management of dyslipidaemias

Reiner, Ž., Catapano, A. L., Backer, G. D., Graham, I. M., Taskinen, M., Wiklund, O., Agewall, S., Alegría, E., Chapman, M. J., Durrington, P. N., et al. (2011) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.09.015 · Cited by 154 · see citing works

Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart

Heise, T., Hövelmann, U., Brøndsted, L., Adrian, C. L., Nosek, L., & Haahr, H. L. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12468 · Cited by 150 · see citing works

DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality

on behalf of the DEVOTE Study Group, Pieber, T. R., Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pratley, R. E., Woo, V. C., Heller, S. R., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4422-0 · Cited by 150 · see citing works

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Marso, S. P., Holst, A. G., & Vilsbøll, T. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1615712 · Cited by 146 · see citing works

The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials

Rados, D. V., Pinto, L. C., Remonti, L. R., Leitão, C. B., & Gross, J. L. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001992 · Cited by 143 · see citing works

Sodium‐glucose cotransporter 2 ( SGLT2 ) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta‐analysis

Ruanpeng, D., Ungprasert, P., Sangtian, J., & Harindhanavudhi, T. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2903 · Cited by 139 · see citing works

Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A B ayesian meta‐analysis of survival data

Bain, S., Druyts, E., Balijepalli, C., Baxter, C. A., Currie, C. J., Das, R., Donnelly, R., Khunti, K., Langerman, H., Leigh, P., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12821 · Cited by 132 · see citing works

Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Maiorino, M. I., Chiodini, P., Bellastella, G., Capuano, A., Esposito, K., & Giugliano, D. (2017) · Diabetes Care · doi:10.2337/dc16-1957 · Cited by 126 · see citing works

Metformin in breast cancer: preclinical and clinical evidence

De, A., & Kuppusamy, G. (2019) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2019.06.003 · Cited by 124 · see citing works

Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study

Abrahami, D., Douros, A., Yin, H., Yu, O. H. Y., Renoux, C., Bitton, A., & Azoulay, L. (2018) · BMJ · doi:10.1136/bmj.k872 · Cited by 122 · see citing works

Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis

Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Hu, N., Juurlink, D. N., Paterson, J. M., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.1522 · Cited by 120 · see citing works

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Pareek, A., Chandurkar, N., & Naidu, K. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1611290 · Cited by 119 · see citing works

Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: The ONSET 2 trial

Bowering, K., Case, C., Harvey, J., Reeves, M., Sampson, M., Strzinek, R., Bretler, D.-M., Bang, R. B., & Bode, B. W. (2017) · Diabetes Care · doi:10.2337/dc16-1770 · Cited by 119 · see citing works

Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure

Sinha, B., & Ghosal, S. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.02.014 · Cited by 113 · see citing works

Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes

Tkáč, I., & Raz, I. (2016) · Diabetes Care · doi:10.2337/dc15-1707 · Cited by 112 · see citing works

Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine ( L antus®) in patients with type 2 diabetes who were insulin‐naïve or previously treated with insulin glargine: a randomized, double‐blind controlled trial (the ELEMENT 2 study)

Rosenstock, J., Hollander, P. A., Bhargava, A., Ilag, L. L., Pollom, R. K., Zielonka, J., Huster, W. J., & PRINCE, M. J. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12482 · Cited by 111 · see citing works

Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: A meta-analysis

Wang, R., Song, Y., Yan, Y., & Ding, Z. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.006 · Cited by 108 · see citing works

Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research

Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s130834 · Cited by 107 · see citing works

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial

Ahmann, A., Rodbard, H. W., Rosenstock, J., Lahtela, J. T., Loredo, L. D., Tornøe, K., Boopalan, A., Nauck, M. A., & on behalf of the NN2211‐3917 Study Group (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12539 · Cited by 105 · see citing works

Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial

Verma, S., Bhatt, D. L., Bain, S. C., Buse, J. B., Mann, J. F. E., Marso, S. P., Nauck, M. A., Poulter, N. R., Pratley, R. E., Zinman, B., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.033898 · Cited by 105 · see citing works

Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials

Monami, M., Nreu, B., Zannoni, S., Lualdi, C., & Mannucci, E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.04.017 · Cited by 103 · see citing works

Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study

Aronson, R., Frías, J. P., Goldman, A., Darekar, A., Lauring, B. P., & Terra, S. G. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13251 · Cited by 99 · see citing works

Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis

Hemmingsen, B., Schroll, J. B., Wetterslev, J., Gluud, C. N., Vaag, A. A., Sonne, D. P., Lundstrøm, L. H., & Almdal, T. (2014) · CMAJ Open · doi:10.9778/cmajo.20130073 · Cited by 97 · see citing works

Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies

Linnebjerg, H., Lam, E. C. Q., Seger, M. E., Coutant, D. E., Chua, L., Chong, C. L., Ferreira, M. M., Soon, D., & Zhang, X. (2015) · Diabetes Care · doi:10.2337/dc14-2623 · Cited by 94 · see citing works

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review

Rådholm, K., Wu, J. H. Y., Wong, M. G., Foote, C., Fulcher, G. R., Mahaffey, K. W., Perkovic, V., & Neal, B. C. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.03.027 · Cited by 94 · see citing works

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

Zhou, Z., Jardine, M., Perkovic, V., Matthews, D. R., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Desai, M. G., Oh, R., Simpson, R., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4955-5 · Cited by 82 · see citing works

Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials

Dicembrini, I., Nreu, B., Scatena, A., Andreozzi, F., Sesti, G., Mannucci, E., & Monami, M. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1031-9 · Cited by 81 · see citing works

Drug repurposing to overcome resistance to various therapies for colorectal cancer

Fong, W., & To, K. K. W. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03134-0 · Cited by 81 · see citing works

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study

Guja, C., Frías, J. P., Somogyi, A., Jabbour, S. A., Wang, H., Hardy, E., & Rosenstock, J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13266 · Cited by 79 · see citing works

SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes

Donnan, K., & Segar, L. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.01.002 · Cited by 76 · see citing works

Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL : 1‐year patient‐level meta‐analysis of the EDITION clinical studies in people with type 2 diabetes

Ritzel, R. A., Roussel, R., Giaccari, A., Vora, J. P., Brulle-Wohlhueter, C., & Yki‐Järvinen, H. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13105 · Cited by 73 · see citing works

Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis

Liu, J., Li, L., Deng, K., Xu, C., Busse, J. W., Vandvik, P. O., Li, S., Guyatt, G. H., & Sun, X. (2017) · BMJ · doi:10.1136/bmj.j2499 · Cited by 70 · see citing works

Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study

But, A., Bruin, M. L. D., Bazelier, M. T., Hjellvik, V., Andersen, M. T., Auvinen, A. P., Starup‐Linde, J., Schmidt, M. K., Furu, K., de Vries, F., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4312-5 · Cited by 68 · see citing works

Liraglutide and Renal Outcomes in Type 2 Diabetes

Mann, J. F. E., Ørsted, D. D., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713042 · Cited by 66 · see citing works

Impact of intensive lifestyle intervention on disability-free life expectancy: the Look AHEAD study

Gregg, E. W., Lin, J., Bardenheier, B., Chen, H., Rejeski, W. J., Zhuo, X., Hergenroeder, A. L., Kritchevsky, S. B., Peters, A. L., Wagenknecht, L. E., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2110 · Cited by 64 · see citing works

Using real‐world data to evaluate the association of incretin‐based therapies with risk of acute pancreatitis: a meta‐analysis of 1 324 515 patients from observational studies

Wang, T., Wang, F., Gou, Z., Tang, H., Li, C., Shi, L., & Zhai, S. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12386 · Cited by 62 · see citing works

The role of an anti-diabetic drug metformin in the treatment of endocrine tumors

Thakur, S., Daley, B., & Kłubo-Gwieździńska, J. (2019) · Journal of Molecular Endocrinology · doi:10.1530/jme-19-0083 · Cited by 62 · see citing works

Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride

Köhler, S., Kaspers, S., Salsali, A., Zeller, C., & Woerle, H. J. (2018) · Diabetes Care · doi:10.2337/dc17-1525 · Cited by 58 · see citing works

The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials

Ling, J., Peng, C., Ge, L., Ding-hua, Z., Shi, A., Tian, J., Chen, Y., Li, X., Zhang, J., & Yang, K. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1222-z · Cited by 55 · see citing works

Does lower limb amputation concern all SGLT2 inhibitors?

Scheen, A. J. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0001-9 · Cited by 50 · see citing works

Objectively Assessed Physical Activity and Weight Loss Maintenance among Individuals Enrolled in a Lifestyle Intervention

Unick, J. L., Gaussoin, S. A., Hill, J. O., Jakicic, J. M., Bond, D. S., Hellgren, M. I., Johnson, K., Peters, A. L., Coday, M., Kitzman, D. W., et al. (2017) · Obesity · doi:10.1002/oby.21971 · Cited by 48 · see citing works

Metformin use and prostate cancer risk

Feng, Z., Zhou, X., Liu, N., Wang, J., Chen, X., & Xu, X. (2019) · Medicine · doi:10.1097/md.0000000000014955 · Cited by 47 · see citing works

Short and medium‐term efficacy of sodium glucose co‐transporter‐2 (SGLT‐2) inhibitors: A meta‐analysis of randomized clinical trials

Monami, M., Liïstro, F., Scatena, A., Nreu, B., & Mannucci, E. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13221 · Cited by 45 · see citing works

Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis

Mishriky, B. M., Tanenberg, R. J., Sewell, K. B., & Cummings, D. M. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.01.017 · Cited by 44 · see citing works

Addition of or switch to insulin therapy in people treated with glucagon‐like peptide‐1 receptor agonists: A real‐world study in 66 583 patients

Montvida, O., Klein, K., Kumar, S., Khunti, K. K., & Paul, S. K. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12790 · Cited by 43 · see citing works

Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy

Home, P., Åhrén, B., Reusch, J. E. B., Rendell, M., Weissman, P. N., Cirkel, D. T., Miller, D. M., Ambery, P., Carr, M. C., & Nauck, M. A. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.06.013 · Cited by 41 · see citing works

Direct head‐to‐head comparison of glycaemic durability of dipeptidyl peptidase‐4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta‐analysis of long‐term randomized controlled trials

Chen, K., Kang, D., Yu, M., Zhang, R., Zhang, Y., Chen, G., & Mu, Y. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13147 · Cited by 40 · see citing works

Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus

Madsen, K. S., Kähler, P., Kähler, L. K. A., Madsbad, S., Gnesin, F., Metzendorf, M., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012368.pub2 · Cited by 40 · see citing works

Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials

Zhuang, X., He, X., Yang, D.-Y. D., Guo, Y., He, J., Xiao, H., & Liao, X. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0722-z · Cited by 39 · see citing works

Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments

Powell, W. R., Christiansen, C. L., & Miller, D. R. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0443-z · Cited by 38 · see citing works

The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose–response of randomized clinical trials

Rahmani, J., Manzari, N., Thompson, J., Gudi, S. K., Chhabra, M., Naik, G., Mousavi, S. M., Varkaneh, H. K., Clark, C. C. T., & Zhang, Y. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02108-9 · Cited by 34 · see citing works

Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial)

Marso, S. P., Nauck, M. A., Fries, T. M., Rasmussen, S., Treppendahl, M. B., & Buse, J. B. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.02.030 · Cited by 32 · see citing works

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus

Lau, I. T., Lee, K. F., So, W. Y., Tan, K. C. B., & Yeung, M. W. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s131358 · Cited by 31 · see citing works

Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review

Xu, S., Zhang, X., Tang, L., Zhang, F., & Tong, N. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2017.1255537 · Cited by 29 · see citing works

Biosimilar vs originator insulins: Systematic review and meta‐analysis

Yamada, T., Kamata, R., Ishinohachi, K., Shojima, N., Ananiadou, S., Nom, H., Yamauchi, T., & Kadowaki, T. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13291 · Cited by 29 · see citing works

Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis

Guo, W., Li, L., Su, Q., Dai, W., & Ye, Z. (2017) · Value in Health · doi:10.1016/j.jval.2017.04.010 · Cited by 26 · see citing works

Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials

Åhrén, B., Carr, M. C., Murphy, K., Perkins, C., Rendell, M., Mallory, J. M., Wilson, T. H., & JOHNSON, S. L. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.02.017 · Cited by 25 · see citing works

A randomized, open-label, comparative, crossover trial on preference, efficacy, and safety profiles of lispro insulin U-100 versus concentrated lispro insulin U-200 in patients with type 2 diabetes mellitus: a possible contribution to greater treatment adherence

Gentile, S., Fusco, A., Colarusso, S., Piscopo, M., Improta, M. R., Corigliano, M., Martedi, E., Oliva, D., Santorelli, A., Simonetti, R., et al. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1453495 · Cited by 25 · see citing works

Fallstricke bei der Diabetesdiagnostik: Wird zu lax mit Laborwerten umgegangen?

Landgraf, R., Nauck, M. A., Freckmann, G., Müller, U., Heinemann, L., Kellerer, M., & Müller‐Wieland, D. (2018) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0673-2156 · Cited by 22 · see citing works

Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials

Li, G., Crowley, M. J., Tang, H., Yang, J. Y., Sandler, R. S., & Wang, T. (2019) · Diabetes Care · doi:10.2337/dc18-1578 · Cited by 22 · see citing works

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio‐vascular outcome trials

Nauck, M. A., Meier, J. J., & Schmidt, W. E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12981 · Cited by 19 · see citing works

Definition, Klassifikation und Diagnostik des Diabetes mellitus

Petersmann, A., Müller‐Wieland, D., Müller, U., Landgraf, R., Nauck, M. A., Freckmann, G., Heinemann, L., & Schleicher, E. D. (2019) · Diabetologie und Stoffwechsel · doi:10.1055/a-0898-7266 · Cited by 17 · see citing works

Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?

Bonadonna, R. C., Renard, É., CHENG, A. Y. Y., Fritsche, A., Cali, A. M. G., Melas‐Melt, L., & Umpierrez, G. E. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.03.041 · Cited by 16 · see citing works

Lack of Evidence for a Harmful Effect of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Fracture Risk among Type 2 Diabetes Patients: A Network and Cumulative Meta-Analysis of Randomized Controlled Trials

Tang, H., Li, D., Zhang, J. J., Hsu, Y., Zhai, S., & Song, Y. (2016) · Author eBooks · Cited by 15 · see citing works

The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) 2018 ESC/ESH Guidelines for the management of arterial hypertension

Editorial, A. (2018) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 13 · see citing works

Therapieziele bei der Hypertoniebehandlung

Düsing, R. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0043-107269 · Cited by 10 · see citing works

Fallstricke bei der Diabetesdiagnostik: Wird zu lax mit Laborwerten umgegangen?

Landgraf, R., Nauck, M. A., Freckmann, G., Müller, U., Heinemann, L., Kellerer, M., & Müller‐Wieland, D. (2018) · Diabetologie und Stoffwechsel · doi:10.1055/a-0762-8219 · Cited by 3 · see citing works

Positionspapier zur Lipidtherapie bei Patienten mit Diabetes mellitus

Parhofer, K. G., Birkenfeld, A. L., Krone, W., Lehrke, M., Marx, N., Merkel, M., Schütt, K. S., Zirlik, A., & Müller‐Wieland, D. (2019) · Diabetologie und Stoffwechsel · doi:10.1055/a-0898-9895 · Cited by 2 · see citing works

Plant Extracts for Type 2 Diabetes: From Traditional Medicine to Modern Drug Discovery

Lee, J., Noh, S., Lim, S., & Kim, B. (2021) · Antioxidants · doi:10.3390/antiox10010081 · Cited by 109 · see citing works

Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025

Roeb, E., Canbay, A. E., Tacke, F., Bantel, H., Bojunga, J., de Laffolie, J., Demir, M., Denzer, U. W., Geier, A., Hofmann, W. P., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2283 · Cited by 102 · see citing works

Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism

Trzaskalski, N. A., Fadzeyeva, E., & Mulvihill, E. E. (2020) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551420912972 · Cited by 86 · see citing works

Effect of traditional Chinese medicine on gut microbiota in adults with type 2 diabetes: A systematic review and meta-analysis

Zheng, Y., Ding, Q., Wei, Y., Gou, X., Tian, J., Li, M., & Tong, X. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153455 · Cited by 62 · see citing works

The management of diabetes mellitus by mangiferin: advances and prospects

Wang, M., Liang, Y., Chen, K., Wang, M., Long, X., Liu, H., Sun, Y., & He, B. (2022) · Nanoscale · doi:10.1039/d1nr06690k · Cited by 56 · see citing works

Phytochemicals and Biological Activities of Walnut Septum: A Systematic Review

Mateș, L., Rusu, M. E., & Popa, D. (2023) · Antioxidants · doi:10.3390/antiox12030604 · Cited by 47 · see citing works

Impact of a Digital Lifestyle Intervention on Diabetes Self-Management: A Pilot Study

Bretschneider, M. P., Klásek, J., Karbanová, M., Timpel, P., Herrmann, S., & Schwarz, P. E. H. (2022) · Nutrients · doi:10.3390/nu14091810 · Cited by 39 · see citing works

Effects of glucagon‐like peptide 1 receptor agonists on testicular dysfunction: A systematic review and meta‐analysis

Salvio, G., Ciarloni, A., Ambo, N., Bordoni, M., Perrone, M., Rossi, S., & Balercia, G. (2025) · Andrology · doi:10.1111/andr.70022 · Cited by 33 · see citing works

Endoscopic Bariatric Treatment with Duodenal-Jejunal Bypass Liner Improves Non-invasive Markers of Non-alcoholic Steatohepatitis

Karlas, T., Petroff, D., Feisthammel, J., Beer, S., Blüher, M., Schütz, T., Lichtinghagen, R., Hoffmeister, A., & Wiegand, J. (2022) · Obesity Surgery · doi:10.1007/s11695-022-06150-5 · Cited by 26 · see citing works

Comparison of SGLT1, SGLT2, and Dual Inhibitor Biological Activity in Treating Type 2 Diabetes Mellitus

Azizogli, A., Vitti, M., Mishra, R., Osorno, L., Heffernan, C., & Kumar, V. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300143 · Cited by 26 · see citing works

Exploring the Potential of Large Language Models in Personalized Diabetes Treatment StrategiesPreprint

Yang, H., Li, J., Liu, S., Du, L., Liu, X., Huang, Y., Shi, Q., & Liu, J. (2023) · medRxiv · doi:10.1101/2023.06.30.23292034 · Cited by 21 · see citing works

Uncovering the effect and mechanism of Panax notoginseng saponins on metabolic syndrome by network pharmacology strategy

Wang, Y., Ma, P., Wang, Z., Sun, M., Hou, B., Xu, T., Li, W., Yang, X., Du, G., Ji, T., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115680 · Cited by 16 · see citing works

Fluorescent Enzymatic Sensor Based Glucose Oxidase Modified Bovine Serum Albumin‐Gold Nanoclusters for Detection of Glucose

Abraham, M. K., Madanan, A. S., Varghese, S., Lekshmi, R. S., Shkhair, A. I., Vijila, N. S., & George, S. (2024) · ChemPlusChem · doi:10.1002/cplu.202300601 · Cited by 16 · see citing works

Effects of an Iranian traditional fermented food consumption on blood glucose, blood pressure, and lipid profile in type 2 diabetes: a randomized controlled clinical trial

Salehi, S. O., Karımpour, F., Imani, H., Ghatee, M. A., Pirouze, M., & Bahramfard, T. (2022) · European Journal of Nutrition · doi:10.1007/s00394-022-02867-2 · Cited by 16 · see citing works

Evaluation of the Impact of Mobile Health App Vitadio in Patients With Type 2 Diabetes: Randomized Controlled Trial

Bretschneider, M. P., Kolasińska, A. B., Šomvárska, L., Klásek, J., Mareš, J., & Schwarz, P. E. (2025) · Journal of Medical Internet Research · doi:10.2196/68648 · Cited by 15 · see citing works

Effectiveness of a Digital Health Application for the Treatment of Diabetes Type II—A Pilot Study

Bretschneider, M. P., Roth, L. M. K., & Schwarz, P. E. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196317 · Cited by 17 · see citing works

Carvacrol improves blood lipid and glucose in rats with type 2 diabetes mellitus by regulating short-chain fatty acids and the GPR41/43 pathway

Sun, Y., Qu, H. Y., Niu, X., Li, T., Wang, L., & Peng, H. (2023) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2024.28.1.1 · Cited by 12 · see citing works

General health of patients with diabetic macular edema—The LIPSIA study

Busch, C., Katzmann, J. L., Jochmann, C., Unterlauft, J. D., Vollhardt, D., Wiedemann, P., Laufs, U., & Rehák, M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252321 · Cited by 11 · see citing works

Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis

Osumili, B., Sapin, H., Yang, Z., Ranta, K., Paik, J. S., & Blüher, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01728-5 · Cited by 12 · see citing works

Managing Type 2 Diabetes Mellitus via the Regulation of Gut Microbiota: A Chinese Medicine Perspective

Ng, C. Y. J., Zhong, L. L. D., Ng, H. S., Goh, K. S., & Zhao, Y. X. (2024) · Nutrients · doi:10.3390/nu16223935 · Cited by 11 · see citing works

Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review

Gravina, A. G., Pellegrino, R., Izzo, M., Costanzo, I. D., Imperio, G., Landa, F., Tambaro, A., & Federico, A. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47050383 · Cited by 10 · see citing works

Decreased in n‐3 DHA enriched triacylglycerol in small extracellular vesicles of diabetic patients with cardiac dysfunction

Ding, W., Zhang, X., Xiao, D., & Chang, W. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13457 · Cited by 8 · see citing works

Adipositas und Diabetes

Aberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Selig, L., Blüher, M., & Menzen, M. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1515-8779 · Cited by 7 · see citing works

Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia

Lasalvia, P., Gil-Rojas, Y., & Peña, Á. A. G. (2022) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2022.2044310 · Cited by 6 · see citing works

Low-intensity Pulsed Ultrasound Stimulation of the Intestine Improves Insulin Resistance in Type 2 Diabetes

Wang, H., He, M., Bat‐Erdene, B., Li, Y., & Ta, D. (2025) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2025.01.004 · Cited by 5 · see citing works

Personalized Diabetes Treatment Support Using Large Language Models Fine-Tuned on Electronic Health Records: Development and Evaluation Study

he, S., Zhang, Y., & li, J. (2026) · JMIR Formative Research · doi:10.2196/71541 · Cited by 5 · see citing works

Simultaneous Determination of Glibenclamide and Silymarin Released from Chitosan Microparticles by HPLC-ESI-MS Technique: Method Development and Validation

Condurache, I., Petrovici, A. R., Simionescu, N., Profire, B.-Ș., Confederat, L. G., Bujor, A., Miron, A., & Profire, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102164 · Cited by 5 · see citing works

Prognostic Value of Histological and Immunohistochemical Data in Diabetic Foot Ulcers

Koreyba, K. A., Silina, E. V., Tsyplakov, D. E., Litvitskiy, P., Manturova, N., Balkizov, Z. Z., Achar, R. R., Raju, N. R., & Stupin, V. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237202 · Cited by 5 · see citing works

Psychiatric disorders in patients with type 2 diabetes mellitus on sodium-glucose cotransporter-2 inhibitors—a nationwide retrospective cohort study

Hu, W., & Lin, C. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02623-1 · Cited by 4 · see citing works

Efficacy and Safety of Insulin Degludec/Insulin Aspart versus Biphasic Insulin Aspart 30 in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials

Niu, Y., Zhang, Y., Song, Z.-Y., Zhao, C.-Z., Luo, Y., Wang, Y., & Yuan, J. (2024) · Iranian Journal of Public Health · doi:10.18502/ijph.v53i2.14916 · Cited by 4 · see citing works

Treatment and associated outcomes of type 2 diabetes mellitus patients with a cardiovascular comorbidity and comparison with guideline recommendations: a German claims data analysis

Aberle, J., Duerschmied, D., Grond, M., Lehrke, M., Martin, S., Tröbs, S., Schultze, M., Kossack, N., Richter, L. M., & Gabler, M. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02864-9 · Cited by 3 · see citing works

Adipositas und Diabetes

Aberle, J., Lautenbach, A., Meyhöfer, S., Schmid, S. M., Selig, L., & Blüher, M. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1179-2778 · Cited by 3 · see citing works

Beyond Blood Sugar: Investigating the Cardiovascular Effects of Antidiabetic Drugs

Ahmad, B. A., Sanghani, I. M., Sayabugari, R., Biju, H., Siddegowda, A., Kinattingal, M. I., Yartha, S. G. R., Gaonkar, P. M., Andrabi, S. S., Vaghamashi, Y., et al. (2023) · Cureus · doi:10.7759/cureus.46373 · Cited by 3 · see citing works

Artesunate Promotes Bone Remodeling Through TRAF6-Mediated NF-κB Signaling Under Orthodontic Stress in Diabetic Rats

Zhan, Y., Zhang, S., Yang, M., Wang, Y., Li, J., & Nong, X. (2025) · International Dental Journal · doi:10.1016/j.identj.2025.04.011 · Cited by 2 · see citing works

Type-2 diabetes patients at high risk for cardiovascular events: time to challenge the ‘metformin-always first’ paradigm

Aboyans, V., & Sattar, N. A. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa157 · Cited by 2 · see citing works

Factors of Influence on Diabetes Awareness in Older People With Chronic Obstructive Pulmonary Disease Comorbid With Type 2 Diabetes Mellitus

Liao, L., Chen, K., CHENG, H.-R., & Hsu, H. (2024) · Journal of Nursing Research · doi:10.1097/jnr.0000000000000602 · Cited by 1 · see citing works

Harnessing Digital Initiatives for Improved Health Outcomes in Diabetes Management: An Observational Patient Program

Sethi, B. K., Seshadri, K., Deshmukh, V. C., Unnikrishnan, A., Baruah, M. P., Phatak, S., Ghosal, S., Chittawar, S., Aggarwal, K., Hs, B., et al. (2024) · Cureus · doi:10.7759/cureus.73093 · Cited by 2 · see citing works

Drug utilization pattern among type II diabetic patients in Palestine

Abualhasan, M., Awad, M., & Sweileh, W. M. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-13028-6 · Cited by 1 · see citing works

How the Salutogenic Pattern of Health Reflects in Type 2 Diabetes Mellitus: A Narrative Review

Mijač, S., Vitale, K., Lončarek, K., & Slivšek, G. (2025) · Diabetology · doi:10.3390/diabetology6110124 · Cited by 1 · see citing works

Randomized controlled trial to evaluate an app-based multimodal digital intervention for people with type 2 diabetes in comparison to a placebo app

Roth, L., Bretschneider, M. P., & Schwarz, P. E. H. (2025) · Frontiers in Digital Health · doi:10.3389/fdgth.2025.1644612 · Cited by 1 · see citing works

Pathophysiology-Oriented Treatment of Type 2 Diabetes: 10 Case Reports

Nováková, N., Nezval, M., & Molnárová, V. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002857 · Cited by 1 · see citing works

Adipositas und Diabetes

Aberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Selig, L., Blüher, M., & Menzen, M. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00903-7 · Cited by 1 · see citing works

Cannabis

Yanar, A. K., & Yazıcı, Z. C. (2023) · Wiley eBooks · doi:10.1002/9781119983347.ch15 · Cited by 1 · see citing works

Gut microbiota modulating therapy for diabetes mellitus should be individualized

Wang, J., Wei, H., Mao, R., & Chang, X. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i10.2152 · Cited by 1 · see citing works

Diabetes mellitus erhöht das Risiko für einen Schlaganfall

Diener, H., & Heni, M. (2020) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-020-1517-9

INFLUENCE OF THIOCTIC ACID N LABORATORY INDICATORS OF CARBOHYDRATE EXCHANGE IN PATIENTS WITH TYPE II DIABETES MELLITUS

Kim, V. S., Abramova, A. N., Shur, Y. V., Selezneva, T. E., Цибизова, А. А., & Avtorhanova, P. M. (2021) · Медико-фармацевтический журнал «Пульс» · doi:10.26787/nydha-2686-6838-2021-23-2-29-35

Efficiency of “Neo inulin” in the complex treatment of patients with type 2 diabetes

Katamanova, E. V., Валерьевна, К. П., Валерьевна, К. И., Kuks, A. N., & Валентиновна, У. О. (2021) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2021-6.6-2.2

Potential Mechanism of Honeysuckle in the Improving of Type 2 Diabetes Mellitus Based on Network Pharmacology and Molecular Docking

刘, 昕. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.121058

Adipositas und Diabetes

Aberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Menzen, M., Selig, L., & Blüher, M. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1886-3659

Adipositas und Diabetes

Aberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Menzen, M., Selig, L., & Blüher, M. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01037-0

Exploring the Potential of Large Language Models in Personalized Diabetes Treatment Strategies (Preprint)Preprint

Yang, H., Li, J., Liu, S., Liu, L., Liu, X., Huang, Y., Shi, Q., & liu, J. (2023) · doi:10.2196/preprints.50911

Correlation of ChREBP Gene Methylation with Pathological Characteristics of Type 2 Diabetes Mellitus

Wang, X., Huangfu, W., & Zhao, F. (2023) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-023-04714-4

Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin‐4‐IgG4‐Fc in healthy subjects: A phase 1, single‐centre, randomized, double‐blind, dose escalation study

Chen, G., Liu, Y., Gao, X., Wu, K., Yang, Y., Chen, Y., Peng, C., Jin, T., Huang, Y., Zhang, Y., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15441

Effects of berberine hydrochloride on intestinal microflora and inflammatory factors in type 2 diabetes model ratsPreprint

Cheng, C., Sha, W., Xu, B., Zhang, C., Xia, J., & Lei, T. (2024) · Research Square · doi:10.21203/rs.3.rs-3335328/v1

Effect of insulin aspart combined with insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus

Wang, H., Li, S., Zhao, T., Pan, X., & Wang, L. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2477074

The Effect of Acupuncture on FPG and HbA1C in Type 2 Diabetes Mellitus: An Overview of Systematic Reviews

王, 媛. (2025) · Traditional Chinese Medicine · doi:10.12677/tcm.2025.144245

LATEST ADVANCES IN INJECTABLE AND ORAL MEDICATIONS FOR TYPE 2 DIABETES TREATMENT

Jurkiewicz, K., Ciechański, M., Kasprzyk, A., Wilk, K., Witkowska, E., Cholewiński, S., Wilk, B., Stachura, P., Rejman, P., & Pszczoła, K. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3883

Analysis of the Genetic Comorbid Mechanisms of Type 2 Diabetes, Alzheimer′s Disease, and Hypertension Using Network Modularization

Tian, S., Zong, W., Zeng, Z., Wang, J., Niu, Q., Zhang, S., Zhang, H., & Li, B. (2026) · BioMed Research International · doi:10.1155/bmri/8877510

Α-gustducine intestinale : implication dans l'obésité et le diabète de type 2

Gléau, L. L. (2021) · theses.fr (ABES) · doi:10.70675/dc436e75zb6d2z4bb4zb9a1z17b025f205a6

Effets de peptides interférents inhibant l’activité de la neuraminidase-1 sur l’activation du récepteur de l’insuline : approche cellulaire et intégrée

Toussaint, K. (2024) · theses.fr (ABES) · doi:10.70675/02ee4897z0b68z4c19zba0cz6cce7622b3d4

Continuous Glucose Monitoring in Insulin-Treated Type 2 Diabetes Mellitus in Sweden: A Scoping Review and Policy Landscape Analysis

JENDLE, J. H., Adolfsson, P., Hellman, J., Klanger, B., & Ekberg, N. R. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261442987

Basal Insulin Adherence in Patients with Type 2 Diabetes Mellitus in Routine Clinical Practice in Spain: Clinical and Economic Impact

Mauricio, D., Pascual, V., Soler, M., & Pérez‐Sádaba, F. J. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01892-2

Therapie des Typ-2-Diabetes

Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2019) · Diabetologie und Stoffwechsel · doi:10.1055/a-0898-9617 · Cited by 25 · see citing works

Praxisempfehlungen DDG/DGIM

Landgraf, R., Kellerer, M., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., Hm, R., et al. (2016) · Diabetologie und Stoffwechsel · doi:10.1055/s-0042-114151 · Cited by 3 · see citing works

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kellerer, M., & Siegel, E. G. (2013) · Diabetologie und Stoffwechsel · doi:10.1055/s-0033-1355642 · Cited by 4 · see citing works

Aktualisierte Versorgungsleitlinie Typ-2-Diabetes fordert alltagstaugliche Therapieziele

Facharztmagazine, R. (2021) · Geriatrie-Report · doi:10.1007/s42090-021-1259-y

Therapie des Typ-2-Diabetes – Praxisempfehlung der DDG

Gallwitz, B., Aberle, J., Birkenfeld, A. L., Kellerer, M., Klein, H. H., Landgraf, R., Müller‐Wieland, D., Müssig, K., Nauck, M., Siegel, E. G., et al. (2026) · Diabetologie und Stoffwechsel · doi:10.1055/a-2866-0999